LCTX Price / Book | Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Lineage Cell Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 5.58, a 26.17% increase year-over-year.
Lineage Cell Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 7.43, a 461.30% increase year-over-year.
Lineage Cell Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 9.37, a 554.54% increase year-over-year.
Lineage Cell Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 18.77, a 607.85% increase year-over-year.
Lineage Cell Therapeutics, Inc. price/book ratio for fiscal 2026 was 5.58.
Lineage Cell Therapeutics, Inc. price/book ratio for fiscal 2025 was 9.37, a 554.54% increase from fiscal 2024.
Lineage Cell Therapeutics, Inc. price/book ratio for fiscal 2024 was 1.43, a 53.47% decline from fiscal 2023.
Lineage Cell Therapeutics, Inc. price/book ratio for fiscal 2023 was 3.08, a 11.16% increase from fiscal 2022.

Available history: 2010-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	5.58	$333.84M	$59.8M
2026-03-31	7.43	$391.4M	$52.7M
2025-12-31	9.37	$406.01M	$43.35M
2025-09-30	18.77	$390.41M	$20.8M
2025-06-30	4.42	$208.47M	$47.11M
2025-03-31	1.32	$102.76M	$77.66M
2024-12-31	1.43	$110.21M	$77.01M
2024-09-30	2.65	$171.84M	$64.79M
2024-06-30	2.82	$188.82M	$66.88M
2024-03-31	3.94	$279.36M	$70.99M
2023-12-31	3.08	$190.74M	$62.02M
2023-09-30	3.1	$206.48M	$66.66M
2023-06-30	3.45	$245.96M	$71.26M
2023-03-31	3.7	$255.26M	$69.02M
2022-12-31	2.77	$199.01M	$71.94M
2022-09-30	2.48	$191.97M	$77.55M
2022-06-30	3.29	$268.2M	$81.5M
2022-03-31	3.07	$261.38M	$85.22M
2021-12-31	4.57	$415.22M	$90.9M
2021-09-30	3.55	$424.53M	$119.59M
2021-06-30	3.85	$476.05M	$123.6M
2021-03-31	3.27	$380.86M	$116.57M
2020-12-31	2.83	$269.45M	$95.13M
2020-09-30	1.56	$140.99M	$90.18M
2020-06-30	1.33	$130.35M	$97.69M
2020-03-31	1.19	$124.35M	$104.76M
2019-12-31	1.2	$133.33M	$111.25M
2019-09-30	1.27	$146.79M	$115.52M
2019-06-30	1.25	$164.61M	$131.76M
2019-03-31	1.21	$195.7M	$161.24M
2018-12-31	1.25	$115.69M	$92.25M
2018-09-30	1.54	$260.87M	$169.56M
2018-06-30	2.18	$228.66M	$104.75M
2018-03-31	2.91	$298.58M	$102.46M
2017-12-31	1.45	$238.64M	$164.26M
2017-09-30	1.38	$287.74M	$208.99M
2017-06-30	1.71	$305.56M	$178.19M
2017-03-31	1.76	$334.62M	$189.7M
2016-12-31	2.49	$324.6M	$130.51M
2016-09-30	2.57	$350.67M	$136.24M
2016-06-30	2.47	$232.16M	$94.05M
2016-03-31	3.81	$227.04M	$59.59M
2015-12-31	3.91	$299.21M	$76.45M
2015-09-30	3.26	$198.65M	$60.93M
2015-06-30	3.54	$229.65M	$64.95M
2015-03-31	5.46	$314.15M	$57.51M
2014-12-31	3.75	$235.5M	$62.72M
2014-09-30	4.44	$173.07M	$38.95M
2014-06-30	3.53	$164.61M	$46.58M
2014-03-31	3.46	$156.85M	$45.36M
2013-12-31	3.9	$164.79M	$42.26M
2013-09-30	6.72	$170.59M	$25.37M
2013-06-30	5.15	$177.76M	$34.52M
2013-03-31	5.4	$162.02M	$29.98M
2012-12-31	5.15	$125.15M	$24.29M
2012-09-30	5.7	$166.65M	$29.21M
2012-06-30	5.36	$183.79M	$34.29M
2012-03-31	4.87	$174.53M	$35.83M
2011-12-31	5.55	$229.94M	$41.46M
2011-09-30	3.71	$174.24M	$46.92M
2011-06-30	4.14	$202.34M	$48.87M
2010-12-31	6.5	$321.21M	$49.43M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	5.58	$333.84M	$59.8M
2025-12-31	9.37	$406.01M	$43.35M
2024-12-31	1.43	$110.21M	$77.01M
2023-12-31	3.08	$190.74M	$62.02M
2022-12-31	2.77	$199.01M	$71.94M
2021-12-31	4.57	$415.22M	$90.9M
2020-12-31	2.83	$269.45M	$95.13M
2019-12-31	1.2	$133.33M	$111.25M
2018-12-31	1.25	$115.69M	$92.25M
2017-12-31	1.45	$238.64M	$164.26M
2016-12-31	2.49	$324.6M	$130.51M
2015-12-31	3.91	$299.21M	$76.45M
2014-12-31	3.75	$235.5M	$62.72M
2013-12-31	3.9	$164.79M	$42.26M
2012-12-31	5.15	$125.15M	$24.29M
2011-12-31	5.55	$229.94M	$41.46M
2010-12-31	6.5	$321.21M	$49.43M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Aligos Therapeutics, Inc. (ALGS)	United States	$0.238B	-0.47
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Protalix BioTherapeutics, Inc. (PLX)		$0.221B	9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)	United States	$0.218B	-18.37
Alector, Inc. (ALEC)	United States	$0.213B	-1.90
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Compass Therapeutics, Inc. (CMPX)	United States	$0.204B	-5.35
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51